6-Keto-PGE1

Synonyms: 6-keto-Prostaglandin E1
6-Keto-PGE1 (6-keto-Prostaglandin E1) 是 PGE1 的生物活性衍生物,可抑制二磷酸腺苷诱导的血小板聚集,降低心脏后负荷,减少血浆心肌抑制因子 (MDF) 聚集,降低动脉血压,扩张血管床,抑制血管平滑肌的血管收缩反应,增加肺顺应性,并可直接稳定分离得到的猫肝脏溶酶体,显著降低 β-葡萄糖醛酸苷酶 (β-glucuronidase) 和组织蛋白酶 D 的释放,从而延长创伤大鼠的存活时间,通过血流动力学和细胞保护作用发挥防护功效,降低中央气道阻力,可用于创伤性休克的相关研究。
产品编号: MS-Y62617 纯度: 99.0% CAS No.: 67786-53-2 分子式: C20H32O6 分子量: 368.46
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg (2.71mM * 1mL in Ethanol)
询价
3-5 天

产品描述

6-Keto-PGE1 (6-keto-Prostaglandin E1) 是 PGE1 的生物活性衍生物,可抑制二磷酸腺苷诱导的血小板聚集,降低心脏后负荷,减少血浆心肌抑制因子 (MDF) 聚集,降低动脉血压,扩张血管床,抑制血管平滑肌的血管收缩反应,增加肺顺应性,并可直接稳定分离得到的猫肝脏溶酶体,显著降低 β-葡萄糖醛酸苷酶 (β-glucuronidase) 和组织蛋白酶 D 的释放,从而延长创伤大鼠的存活时间,通过血流动力学和细胞保护作用发挥防护功效,降低中央气道阻力,可用于创伤性休克的相关研究。

生物实验数据

生物活性 6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1 that inhibits adenosine diphosphate-induced platelet aggregation, reduces cardiac afterload, decreases plasma myocardial depressant factor (MDF) accumulation, lowers arterial blood pressure, dilates the vascular bed, suppresses the vasoconstrictor response of vascular smooth muscle, increases pulmonary compliance, and directly stabilizes isolated feline liver lysosomes, significantly reducing the release of β-glucuronidase and cathepsin D, thereby prolonging the survival time of traumatized rats and exerting protective effects through hemodynamic and cytoprotective actions, and reduces central airway resistance, making it useful for research related to traumatic shock.
IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

6-Keto-PGE1 (1 μg/mL; 30 min) 可直接稳定分离得到的猫肝脏溶酶体,显著降低 β-葡萄糖醛酸苷酶和组织蛋白酶 D 的释放。

体内研究
(In Vivo)

6-Keto-PGE1 (250 ng/kg/min;静脉注射;持续输注,于创伤后 15 分钟启动并持续至实验结束) 可显著将创伤休克大鼠的存活时间延长至 2.6 h,同时降低血浆组织蛋白酶 D 和 MDF 水平,并稳定平均动脉血压。
6-Keto-PGE1 (250 ng/kg/min;静脉注射;持续输注;5 小时) 可使假手术健康大鼠的平均动脉血压出现轻度持续性下降 (5 小时时总降幅为 23 mmHg),且不改变其心率。
6-Keto-PGE1 (1 μg/min;动脉内输注) 可使猫肠系膜灌注压力显著降低约 27-31%,并可逆性抑制猫肠系膜血管床对交感神经刺激、去甲肾上腺素及血管紧张素 II 的血管收缩反应。
6-Keto-PGE1 (0.3-10 μg;静脉注射;快速推注) 可在 5-HT (MS-V54767) 诱导支气管收缩的猫体内发挥强效支气管扩张作用,其降低中央气道阻力的效力比 PGI2 高 3-10 倍,且肺血管舒缩活性极低,同时其作用不依赖于环氧合酶通路的激活。

Animal Model: Sprague-Dawley (male, 210-250 g, traumatic shock induced by Noble-Collip drum trauma under sodium pentobarbital anesthesia)
Dosage: 250 ng/kg/min
Administration: i.v.; continuous infusion; starting 15 min after trauma for experiment duration
Result: Prolonged mean survival time to 2.6 hours.
Inhibited trauma-induced increase in plasma cathepsin D activity, reducing it from ~14 units/mg protein to ~9 units/mg protein.
Reduced plasma MDF activity from ~58 units to ~30 units.
Increased mean arterial blood pressure to 108 mmHg at 0.5 hours and maintained this level for 2 hours in 7 out of 10 treated rats.
Animal Model: Sprague-Dawley (male, 210-250 g, sham-operated, no trauma)
Dosage: 250 ng/kg/min
Administration: i.v.; continuous infusion; 5 hours
Result: Decreased mean arterial blood pressure by 15 mmHg 5 minutes after infusion start, followed by a 10 mmHg increase by 15 minutes.
Maintained a mean arterial blood pressure of 117 mmHg at 5 hours, down from an initial 140 mmHg.
Caused no significant changes in heart rate.
Animal Model: Domestic cats (adult, either sex, 1.9 to 4.3 kg)
Dosage: 1 μg/min
Administration: i.a.; infusion
Result: Reduced mesenteric arterial perfusion pressure from a control of 105 mmHg to 76 mmHg at 1 minute, 73 mmHg at 3 minutes, 72 mmHg at 5 minutes, 77 mmHg at 10 minutes, and 76 mmHg at 30 minutes.
Returned perfusion pressure to baseline (105 mmHg) 30 minutes after infusion cessation.
Reduced vasoconstrictor responses to all tested doses of norepinephrine (0.3, 1, 3 μg i.a.), all tested frequencies of sympathetic nerve stimulation (1, 3, 10 cycles/sec), and all tested doses of angiotensin II (0.3, 1 μg i.a.) during infusion.
Restored all suppressed vasoconstrictor responses to control levels 30 minutes after infusion termination.
Animal Model: Mongrel cats (either sex, 2.0-4.5 kg)
Dosage: 0.3 μg; 1.0 μg; 3.0 μg; 10.0 μg
Administration: i.v.; rapid injection
Result: Produced statistically significant reductions in central airway resistance (RL) and increases in dynamic lung compliance (Cdyn) and semi-static compliance (C'stat') compared to 5-HT-elevated tone controls.
Decreased RL from 38 cm H2O/L/sec to 35 cm H2O/L/sec, increased Cdyn from 4.0 mL/cm H2O to 4.5 mL/cm H2O, increased C'stat' from 3.2 mL/cm H2O to 3.5 mL/cm H2O, and caused no significant change in pulmonary arterial pressure (PPA) at 0.3 μg.
Decreased RL from 38 cm H2O/L/sec to 32 cm H2O/L/sec, increased Cdyn from 4.4 mL/cm H2O to 4.9 mL/cm H2O, increased C'stat' from 3.4 mL/cm H2O to 3.9 mL/cm H2O, and caused no significant change in PPA at 1.0 μg.
Decreased RL from 34 cm H2O/L/sec to 27 cm H2O/L/sec, increased Cdyn from 4.4 mL/cm H2O to 5.2 mL/cm H2O, increased C'stat' from 3.5 mL/cm H2O to 4.5 mL/cm H2O, and decreased PPA significantly from 25 mm Hg to 23 mm Hg at 3.0 μg.
Decreased RL from 32 cm H2O/L/sec to 22 cm H2O/L/sec (a 32% reduction from elevated tone, representing a 50% return to pre-5-HT control values), increased Cdyn from 5.3 mL/cm H2O to 6.2 mL/cm H2O, increased C'stat' from 4.1 mL/cm H2O to 5.1 mL/cm H2O, and caused no significant change in PPA at 10.0 μg.
Was 3-10 times more potent than PGI2 at reducing RL, and more potent than PGI2 at increasing Cdyn at lower doses.
Had a time to maximum response (tmax) ranging from 30 seconds to 42 seconds, which was significantly shorter than tmax for PGI2 at comparable potency doses.
Had a duration of response (t1/2) ranging from 52 seconds to 103 seconds, with no consistent difference compared to PGI2.
Showed airway and vascular responses unaltered by pretreatment with sodium meclofenamate.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 368.46
分子式 C20H32O6
CAS No. 67786-53-2
别名 6-keto-Prostaglandin E1

储存&溶解度

溶解度信息
PBS (pH 7.2): >1.6 mg/mL (from PGE1), Sonication is recommended.
DMF: >100 mg/mL (from PGE1), Sonication is recommended.
DMSO: >50 mg/mL (from PGE1), Sonication is recommended.
Ethanol: >50 mg/mL (from PGE1), Sonication is recommended.
储存方式

Solution, -20°C, 2 years

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础